CONTENTS

SHORT COMMUNICATIONS

Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics. Birk Poller, Dilek Iusuf, Rolf W. Sparidans, Els Wagenaar, Jos H. Beijnen, and Alfred H. Schinkel ............... 729


ARTICLES


Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CY3A5-Mediated Midazolam 1’-Hydroxylation. Minako Sugiyama, Ken-ichi Fujita, Norie Murayama, Yoko Akiyama, Hiroshi Yamazaki, and Yasutaka Sasaki .................. 757

Novel Cytochrome P450-Mediated Ring Opening of the 1,3,4-Oxadiazole in Setileuton, a 5-Lipoxygenase Inhibitor. Cheri M. Maciokel, Bennett Ma, Karsten Menzel, Sebastien Laliberte, Kevin Bateman, Paul Kroliekowski, and Christoper R. Gibson ........... 763

Influence of Drug Solubility and Lipophilicity on Transcleral Retinal Delivery of Six Corticosteroids. Ashish Thakur, Rajendra S. Kadam, and Uday B. Komppela .................. 771


Contribution of Carboxylesterase in Hamster to the Intestinal First-Pass Loss and Low Bioavailability of Ethyl Piperate, an Effective Lipid-Lowering Drug Candidate. Youli Lu, Nairun Bao, Gereltu Borjihan, Yanling Ma, Miaomiao Hu, Chen Yu, Shujun Li, Jingying Jia, Ding Yang, and Yiping Wang .......... 796

Metabolism of the c-Fos/Activator Protein-1 Inhibitor T-5224 by Multiple Human UDP-Glucuronosyltransferase Isoforms. Shin-Suke Uchihashi, Hiroyuki Fukumoto, Makoto Onoda, Hiroyoshi Hayakawa, Shin-Ichi Ikushiro, and Toshiyuki Sakaki .................. 803

Organic Anion Transporter 3 Mediates the Efflux Transport of an Amphipathic Organic Anion, Dehydroepiandrosterone Sulfate, across the Blood-Brain Barrier in Mice. Mari Miyajima, Hiroyuki

Continued on next page
Contents (cont’d.)

Kusuhara, Miki Fujishima, Yasuhisa Adachi, and Yuichi Sugiyama .......................................................... 814


Evaluation of the Effects of 20 Nonsynonymous Single Nucleotide Polymorphisms of CYP2C19 on S-Mephenytoin 4′-Hydroxylation and Omeprazole 5′-Hydroxylation. Huijuan Wang, Nianzhen An, Hao Wang, Yiwen Gao, Duan Liu, Ting Bian, Juanli Zhu, and Chao Chen .......................................................... 830

CYP2C9-Mediated Metabolic Activation of Losartan Detected by a Highly Sensitive Cell-Based Screening Assay. Atsushi Iwamura, Tatsuki Fukami, Hiroko Hosomi, Miki Nakajima, and Tsuyoshi Yokoi .......................................................... 838

In Vivo Investigation in Pigs of Intestinal Absorption, Hepatobiliary Disposition, and Metabolism of the 5α-Reductase Inhibitor Finasteride and the Effects of Coadministered Ketoconazole. Anna Lundahl, Mikael Hedeland, Ulf Bondesson, and Hans Lennernäs .......................................................... 847

Optimal Experimental Design for Assessment of Enzyme Kinetics in a Drug Discovery Screening Environment. Erik Sjögren, Joakim Nyberg, Mats O. Magnusson, Hans Lennernäs, Andrew Hooker, and Ulf Bredberg .......................................................... 858

Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data. Helen E. Cubitt, J. Brian Houston, and Aleksandra Galelin .......................................................... 864

Differential Role of Toll-Interleukin 1 Receptor Domain-Containing Adaptor Protein in Toll-Like Receptor 2-Mediated Regulation of Gene Expression of Hepatic Cytokines and Drug-Metabolizing Enzymes. Romi Ghose, Tao Guo, Jesus G. Vallejo, and Adarsh Gandhi .......................................................... 874

Liver-Selective Expression of Human Arylamine N-Acetyltransferase NAT2 in Transgenic Mice. Kim S. Sugamori, Debbie Brenneman, and Denis M. Grant .......................................................... 882

Metabolism and Disposition of [14C]Brivanib Alamine after Oral Administration to Rats, Monkeys, and Humans. Jiachang Gong, Jinping Gan, Janet Caceres-Cortes, Lisa J. Christopher, Vinod Arora, Eric Masson, Daphne Williams, Janice Parsley, Alban Allentoff, Michael Lago, Scott B. Tran, and Ramaswamy A. Iyer .......................................................... 891

Reevaluation of the Microsomal Metabolism of Montelukast: Major Contribution by CYP2C8 at Clinically Relevant Concentrations. Anne M. Filppula, Jouko Laitila, Pertti J. Neuvonen, and Janne T. Backman .......................................................... 904

The Development of UDP-Glucuronosyltransferases 1A1 and 1A6 in the Pediatric Liver. Shogo J. Miyagi and Abby C. Collier .......................................................... 912

Interactions of Green Tea Catechins with Organic Anion-Transporting Polypeptides. Megan Roth, Barbara N. Timmermann, and Bruno Hagenbuch .......................................................... 920

Effect of the CYP2C8 Genotype on the Pharmacokinetics and Pharmacodynamics of Repaglinide. Dorota Tomalik-Scharte, Uwe Fuhr, Martin Hellmich, Dorothee Frank, Oxana Doroshchenko, Alexander Jetter, and Julia C. Stingl .......................................................... 927

ACCELERATED COMMUNICATION
Seasonal Variation in Blood Drug Concentrations and a Potential Relationship to Vitamin D. Jonatan D. Lindh, Marine L. Andersson, Erik Eliasson, and Linda Björkhem-Bergman .......................................................... 933

ERRATUM
Correction to Table of Contents, Volume 39, Number 3, March 2011 .......................................................... 938

□ Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: Proposed metabolism of LY654322 to form M25. See the article by Borel et al. on page 740 of this issue.